Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells

BACKGROUND: Drug resistance is a major problem in the treatment of leukemia with doxorubicin (Dox), and the erythroblastosis virus E26 oncogene homolog 1 (ETS1) gene is associated with drug resistance. Olmutinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jiansheng, Zhang, Jinli, Yu, Xiaoyang, Zhang, Xing, Dian, Linping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466836/
https://www.ncbi.nlm.nih.gov/pubmed/32830792
http://dx.doi.org/10.12659/MSM.924922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466836/
https://www.ncbi.nlm.nih.gov/pubmed/32830792
http://dx.doi.org/10.12659/MSM.924922

Ejemplares similares